Literature DB >> 498414

Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

M Beran, B Andersson, S Eksborg, H Ehrsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 498414     DOI： 10.1007/bf00253100

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  15 in total

1.  Pharmacological and therapeutic efficacy of daunomycin:DNA complex in mice.

Authors:  T Ohnuma; J F Holland; J H Chen
Journal:  Cancer Res       Date:  1975-07       Impact factor: 12.701

2.  Adriamycin (NSC-123127) and its analogs.

Authors:  D W Henry
Journal:  Cancer Chemother Rep 2       Date:  1974-12

3.  Daunorubicin-DNA: further clinical trials in acute non-lymphoblastic leukemia.

Authors:  G Cornu; J L Michaux; G Sokal; A Trouet
Journal:  Eur J Cancer       Date:  1974-11       Impact factor: 9.162

4.  Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Authors:  A Trouet; D Deprez-de Campeneere; C De Duve
Journal:  Nat New Biol       Date:  1972-09-27

5.  Letter: DNA-daunorubicin complex: preliminary trials in human leukaemia.

Authors:  G Sokal; A Trouet; J L Michaux; G Cornu
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

6.  Human bone marrow colony growth in agar-gel.

Authors:  B L Pike; W A Robinson
Journal:  J Cell Physiol       Date:  1970-08       Impact factor: 6.384

7.  Prognostic value of colony-stimulating and colony-forming cells in peripheral blood in acute non-lymphoblastic leukemia.

Authors:  P Hörnsten; M Granström; B Wahren; G Gahrton
Journal:  Acta Med Scand       Date:  1977

8.  Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.

Authors:  S Eksborg; H Ehrsson; B Andersson; M Beran
Journal:  J Chromatogr       Date:  1978-06-01

9.  Reversed-phase liquid chromatography of adriamycin and daunorubicin and their hydroxyl metabolites adriamycinol and daunorubicinol.

Authors:  S Eksborg
Journal:  J Chromatogr       Date:  1978-02-11

10.  A simplified in vitro classification for prognosis in adult acute leukemia: the application of in vitro results in remission-predictive models.

Authors:  G Spitzer; K A Dicke; E A Gehan; T Smith; K B McCredie; B Barlogie; E J Freireich
Journal:  Blood       Date:  1976-12       Impact factor: 22.113
View more
  7 in total

1.  Cells resistant to cytotoxic drugs are recognized by monoclonal antibody.

Authors:  C J O'Hara; J Grover; G B Price
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

2.  AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.

Authors:  Linlin Zhong; Honglin Shen; Chenfei Huang; Hongwu Jing; Deliang Cao
Journal:  Toxicol Appl Pharmacol       Date:  2011-05-26       Impact factor: 4.219

3.  Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells.

Authors:  S Seeber; H Loth
Journal:  Blut       Date:  1981-06

4.  DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.

Authors:  Y J Schneider; R Baurain; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.

Authors:  B Andersson; M Beran
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.